Castle Biosciences, Inc.

NASDAQ:CSTL

Medical - Diagnostics & Research

Healthcare
$33.38 +0.20%

+$0.04 today

Market cap
$1.03B
Beta
1.02
P/E (TTM)
-47.3
EPS (TTM)
-$0.43
52W Low $14.59High $44.28

Volume 0.38M

Average 0.37M

CSTL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Castle Biosciences, Inc.NASDAQ: CSTL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 72.2%

Gross margin was 72.2% in Q1 FY2026, down 9.2 pp from a year earlier. On a trailing-twelve-month basis it was 77.1%, down 4.9 pp year over year. Over 3 fiscal years it widened by 2.7 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
72.2%-6.8 pp QoQ
Last fiscal yearDec 2025
79.4%-2.5 pp YoY
LTMMar 2026
77.1%-4.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-9.2 pp——
1 year-2.5 pp——
3 years+2.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
79.4%
Year-over-year change
-2.5pp

Gross Margin vs competitors

How CSTL compares with its peers on the latest reported figures

  • CSTL's LTM Mar 2026 gross margin of 77.1% is the 2nd highest of the 8 companies compared; the peer median is 65.2%.
  • Its year-over-year change of -4.9 pp is the 7th highest of 8, against a peer median of -0.0 pp.
  • Over three fiscal years its change of +2.7 pp compares with a peer median of +2.9 pp.
CSTL Competitors Peer median
Gross Margin for CSTL and competitors
Company Period LTM level YoY 3-year change
BDSXBiodesix, Inc.LTM Mar 202682.1% +3.7 pp+18.1 pp
CSTLCastle Biosciences, Inc.LTM Mar 202677.1% -4.9 pp+2.7 pp
VCYTVeracyte, Inc.LTM Jun 202672.1% +3.8 pp+3.9 pp
MYGNMyriad Genetics, Inc.LTM Mar 202670.0% -0.0 pp-0.3 pp
GHGuardant Health, Inc.LTM Sep 202665.2% +1.4 pp-0.8 pp
MDXHMDxHealth S.A.FY202559.7% -1.5 pp+7.9 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
PSNLPersonalis, Inc.LTM Mar 202613.7% -19.6 pp—
FRNMFreenome, Inc. Common stock—— ——
Peer median (excluding CSTL) 65.2%-0.0 pp+2.9 pp

Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.09M137.04M219.79M332.07M344.23M
Cost of Revenue15.82M32.01M44.98M60.21M71.03M
Gross Profit78.26M105.03M174.81M271.86M273.2M
Gross Margin83.2%76.6%79.5%81.9%79.4%
Research & Development29.65M44.9M53.62M52.04M51.85M
Selling, General & Admin86.74M143M180.15M200.05M229.32M
Operating Expenses118.34M177.89M242.78M263.19M316.01M
Depreciation & Amortization3.41M10.54M12.33M16M40.77M
EBITDA(36.6M)(58.34M)(45.02M)38.14M11.34M
EBITDA Margin-38.9%-42.6%-20.5%11.5%3.3%
Operating Income(40.08M)(72.86M)(67.98M)8.67M(42.81M)
Operating Margin-42.6%-53.2%-30.9%2.6%-12.4%
Interest Income68K3.97M10.62M12.92M11.77M
Interest Expense1K17K11K577K86K
Other Income / Expenses67K3.95M10.61M12.89M13.3M
Income Before Tax(40.01M)(68.9M)(57.37M)21.56M(29.51M)
Pre-Tax Margin-42.5%-50.3%-26.1%6.5%-8.6%
Income Tax Expense(8.72M)(1.77M)101K3.32M(5.36M)
Net Income(31.29M)(67.14M)(57.47M)18.25M(24.16M)
Net Margin-33.3%-49.0%-26.1%5.5%-7.0%
EPS (Basic)(1.24)(2.58)(2.14)0.66(0.83)
EPS (Diluted)(1.24)(2.58)(2.14)0.62(0.83)
Weighted Avg Shares25.14M26.05M26.8M27.78M28.99M
Weighted Avg Shares (Diluted)25.14M26.05M26.8M29.26M28.99M

Castle Biosciences, Inc.

NASDAQ:CSTL

Intrinsic Alpha fair value

Locked

Current Price

$33.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.